Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

About this update from Incyte Corporation

[{"type":"text","content":"\n- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted\n\n\n- Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo\n\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver.\n\n\n“At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.”\n\n\nDetails on key data presentations at AAD include:\n\n\nLate-Breaking Oral Presentations\n\n\nHidradenitis Suppurativa\n\n\nPovorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies\n(Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00 p.m. MT)\n\n\nePoster Exhibits\n\n\nAtopic Dermatitis\n\n\nRuxolitinib Cream Improves Patient-Reported Outcomes in Adults With Moderate Atopic Dermatitis (TRuE-AD4)\n​(Abstract #: 75312)\n\n\nRuxolitinib Cream Is Efficacious in Adults With Moderate Atopic Dermatitis Regardless of Baseline Disease Severity and Previous Medication History\n​(Abstract #: 70667)\n\n\nHidradenitis Suppurativa\n\n\nPovorcitinib for Moderate-to-Severe Hidradenitis Suppurativa: Week 24 Interim Phase 3 Results in Anti-TNF-Experienced Patients\n(Abstract #: 75195)\n\n\nPhysician Perspectives on Diagnosis and Treatment of Hidradenitis Suppurativa: Results From the Global HERALD (Hidradenitis Suppurativa Experiences in the Real World) Survey\n​(Abstract #: 75265)\n\n\nDisease Burden and Treatment History of Hidradenitis Suppurativa: Patient Perspectives From the Global HERALD (Hidradenitis Suppurativa Experiences in the Real World) Survey\n​(Abstract #: 75268)\n\n\nVitiligo\n\n\nAssociation Be...

More updates from Incyte Corporation